▪ Abstract As many more clinical trials collect economic information within their study design,
so health economics analysts are increasingly working with patient-level data on both costs …

Hypertension is a growing public health problem worldwide. Only 37% of American
hypertensives currently have their blood pressures controlled. Hypertension is traditionally …

The statistical analysis of cost-effectiveness data is becoming increasingly important within
health and medical research. Statistical Analysis of Cost-Effectiveness Data provides a …

This paper discusses the definition, interpretation and computation of cost‐effectiveness
(CE) acceptability curves. A formal definition of the CE acceptability curve based on the net …

The aim of this paper is to briefly outline a Bayesian approach to cost‐effectiveness analysis
(CEA). Historically, frequentists have been cautious of Bayesian methodology, which is often …

The authors present an analysis of the choice of sample sizes for demonstrating cost-
effectiveness of a new treatment or procedure, when data on both cost and efficacy will be …

No consensus has yet been reached on how to analyse uncertainty in economic evaluation
studies where individual patient data are available for costs and health effects. This paper …

In the last decade, major advances have been made in the statistical methods for quantifying
uncertainty in stochastic cost-effectiveness studies. In this paper, we provide a guide to the …

We present a general Bayesian framework for cost‐effectiveness analysis (CEA) from
clinical trial data. This framework allows for very flexible modelling of both cost and efficacy …

Aim To determine the prevalence of diabetes complications and associated risk factors
among people with type 2 diabetes in three Pacific Island countries, Nauru, Solomon Islands …